Andria Sirur

Dr. Andria Sirur

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in Health Economics, Policy and Law
Verified
Journal Article
Open access
PDF file
ASAndria Sirur
Andria Sirur
RKRajasekharan Pillai K
Rajasekharan Pillai K
The management implications of pricing healthcare services, especially hospitals, have received insufficient scholarly attention. Additionally, disciplinary overlaps have led to scattered academic efforts in this domain. This study performs a thematic synthesis of the literature and applies retrospective analysis to hospital service pricing articles to address these issues. The study's inputs were sourced from well-known online repositories, using a structured search string and PRISMA flow chart to select the pertinent documents. Our thematic analysis of pricing literature encompasses: (a) comprehension of hospital service pricing nature; (b) pricing objectives, strategies and practices differentiation; (c) presentation of factors impacting hospital service pricing. We observe that hospital pricing is an intricate and unclear matter. The terms ‘pricing strategies’ and ‘pricing practices’ are often used interchangeably in academic literature. Hospital service pricing is influenced by costs, demand and supply factors, market structure, pricing regulation and third-party reimbursements. The study's findings provide policy implications for service pricing in hospitals, in addition to suggesting avenues for future research on hospital pricing.

27 June 2024 in JBI Evidence Synthesis
Verified
Journal Article
Closed access
MAMona Thangamma Ag
Mona Thangamma Ag
BVBhavya Vidyadharan
Bhavya Vidyadharan
RDRoshan P. Daniel
Roshan P. Daniel
ASAndria Sirur
Andria Sirur
PKPraveen Kumar
Praveen Kumar
DJDenny John
Denny John
Objective: This review will synthesize studies on costs, the impact of these costs, and the cost-effectiveness of treatments for rheumatic heart disease (RHD) in low- and middle-income countries. Introduction: RHD incurs high costs owing to its clinical complexity, surgical treatments, and prolonged hospital stays. Thus, the disease has a substantial economic impact on the health system, patients, and their families. No systematic review on economic evidence of treatments for RHD has been published to date. Inclusion criteria: This review will consider all cost and cost-effectiveness studies on RHD treatments for children and young adults (5─30 years) residing in low- and middle-income countries. Methods: The review will follow the JBI methodology for systematic reviews of economic evaluation evidence. The search strategy will locate published and unpublished studies in English. Systematic searches will be conducted in MEDLINE (PubMed), MEDLINE (Ovid), Embase (Ovid), Scopus, CINAHL (EBSCOhost), National Health Service Economic Evaluation Databases, Pediatric Economic Database Evaluation, and Cost-Effectiveness Analysis Registry. Two independent reviewers will screen titles and abstracts, followed by a full-text review based on the inclusion criteria. Data will be extracted using a modified JBI data extraction form for economic evaluations. JBI’s Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the results of cost and cost-effectiveness studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence for outcomes related to resource use. Review registration: PROSPERO CRD42023425850

7 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RKRajesh Kamath
Rajesh Kamath
SBSanjay Kini B
Sanjay Kini B
VPVidya Prabhu
Vidya Prabhu
ASAndria Sirur
Andria Sirur
Background/Objectives: Cancer diagnosed before the age of 50 is rising across many countries, and the rise is not accounted for by population growth alone. India carries one of the world’s largest cancer burdens, and it varies greatly between its states, variation camouflaged by the national average. We characterised early-onset breast, cervical, colorectal and stomach cancer across the states of India. Methods: Secondary ecological analysis of Global Burden of Disease Study 2023 estimates, ages 15–49 years, 1990–2023; rates per 100,000 population of both sexes. Trends were summarised as the estimated annual percentage change, with autocorrelation-robust confidence intervals, and by segmented regression. Gradients across 30 states were assessed against the 2023 Socio-Demographic Index (SDI). Case growth was decomposed into population growth, within-band ageing and rate change. Results: In 2023, breast cancer had the highest early-onset incidence, 9.63 per 100,000 (19.63 per 100,000 women), and cervical cancer 8.18 (16.87). Breast incidence rose 2.72% per year and colorectal 1.11%; stomach fell 0.52%. Cervical incidence fell until 2011 and rose unevenly thereafter, with a near-zero net trend (−0.09% per year). Within-band standardisation shifted it downward (−0.39%; 95% confidence interval −0.87 to 0.09), and separating within-band ageing turned its rate-change share negative (−8.1%). Breast cases rose from 15,550 to 76,806: 59.0% of the rise was rate change, 51.8% after separating ageing. Point estimates suggested a stronger inverse SDI gradient for cervical disability-adjusted life years (ρ = −0.43) than incidence (ρ = −0.31). Neither survived multiple-testing correction, and the two were not distinguishable. No association was detected between burden rate and caseload across the states (ρ = +0.02). Conclusions: The early-onset cancer burden in India is not uniform. Breast cancer cases are growing faster than the population, with a rising recorded rate. The cervical gradient is exploratory. The states with the highest rates and the states with the most cases differ, and each answers a different planning question.

25 January 2025 in Evidence Public Health
Verified
Journal Article
Open access
PDF file
MAMona Thangamma Ag
Mona Thangamma Ag
SRShree Rath
Shree Rath
ASAndria Sirur
Andria Sirur
VUVijaya Kumar Uthakalla
Vijaya Kumar Uthakalla
Santenna Chenchula MS, PhDSantenna Chenchula MS, PhD
Santenna Chenchula MS, PhD
SYSree Sudha T Y
Sree Sudha T Y
Background: Colorectal cancer, one of the most prevalent cancers globally, originates from polyps in the colon or rectum, which can develop into cancer over time. It remains a leading cause of cancer-related deaths, imposing significant economic and healthcare burdens. As the incidence of colorectal cancer continues to rise, particularly in developing healthcare systems, understanding the economic impact of treatment options is critical for informing clinical decisions and shaping healthcare policies. Methods: Following PRISMA guidelines, an extensive literature search was conducted through databases including PubMed, Embase, and Scopus up to 7 October 2024. The inclusion criteria targeted studies utilizing cost-effectiveness analysis frameworks like Markov and Partitioned-Survival models, comparing fruquintinib to other cancer treatments. Key outcome measures focused on Incremental Cost-Effectiveness Ratios and Quality-Adjusted Life Years. Results: Of the 49 articles screened, seven studies were eligible for inclusion. These studies provided a detailed economic evaluation of Fruquintinib against Regorafenib, placebo, and best supportive care. Notably, Fruquintinib was cost-effective in the Chinese healthcare setting with an ICER of $26,508 per QALY compared to $35,607 for Regorafenib. However, it did not meet cost-effectiveness thresholds when compared with placebo, with an ICER exceeding three times the GDP per capita in China, reflecting the economic challenges of implementing new cancer treatments. Conclusion: Fruquintinib shows promise as a cost-effective treatment for metastatic colorectal cancer, particularly in healthcare settings like China, providing significant QALY gains compared to traditional therapies. However, its adoption is highly dependent on local economic thresholds and healthcare systems. While this study underscores the need to integrate economic and clinical outcomes in cancer treatment decisions, the drug's approval and data are currently limited to China, making it difficult to conclude its cost-effectiveness globally